- Open Access
Transplanters drive CARs to the clinic by brewing ICE-T: the Moffitt roadmap
© The Author(s). 2017
- Received: 27 March 2017
- Accepted: 4 July 2017
- Published: 18 July 2017
Recent single institution clinical trial successes with anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for B cell malignancies attracted significant attention from industry. Our center sought to rapidly and safely bring industry sponsored pivotal trials to our patients and to prepare for additional cell therapy trials in solid and liquid tumors from both industry and our own investigators. We implemented a collaborative cross departmental program to provide clinical care and trial coordination for immune cell therapies. The Moffitt Immune Cell Therapy (ICE-T) program oversees and administers not only CAR T cell therapy for hematologic malignancies, but TIL and TCR therapy for solid tumor patients. Disease specific experts maintain oversight as principal investigators of these key trials yet the coordination and clinical care is centralized to leverage the expertise and infrastructure of our already robust Blood and Marrow Transplantation program.
- Chimeric antigen receptor (CAR) therapy
- Cytotoxic T lymphocytes
- Cell therapy
- T cell receptor (TCR) therapy
- Tumor infiltrating lymphocyte (TIL) therapy
- Cytokine release syndrome
We thank the Faculty of the Department of Malignant Hematology and the Department of Blood & Marrow Transplant and Cellular Immunotherapy; all members of the Moffitt Immunotherapy Working Group; physicians, advanced practice professionals, nurses, social workers and staff that care for Moffitt Immune Cell Therapy patients; and the clinical trial coordinators and data managers of the Immune Cell Therapy Clinical Trial Office group.
This work was supported by NCI P30 CA076292 (PI: Sellers) and NCI K23-CA201594 (PI: Locke) and was acknowledged by a NCI Cancer Clinical Investigator Team Leadership Award (Locke).
Availability of data and materials
All authors contributed to the manuscript. Both authors read and approved the final manuscript.
Ethics approval and consent to participate
Consent for publication
Both F.L.L. and C.A. consent to publish this commentary.
F.L.L. has served as a compensated scientific advisor to Kite pharma and a consultant to Cellular Biomedicine Group Inc.; C.A. declares no conflicts.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385(9967):517–28.View ArticlePubMedGoogle Scholar
- Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–17.View ArticlePubMedPubMed CentralGoogle Scholar
- Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9.View ArticlePubMedGoogle Scholar
- Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.View ArticlePubMedPubMed CentralGoogle Scholar
- Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21(8):914–21.View ArticlePubMedPubMed CentralGoogle Scholar
- Brower V. The CAR T-Cell Race. http://www.the-scientist.com/?articles.view/articleNo/42462/title/The-CAR-T-Cell-Race/. Accessed 5 July 2017.
- Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285–95.View ArticlePubMedGoogle Scholar
- Maus MV, Nikiforow S. The why, what, and how of the new FACT standards for immune effector cells. J Immunother Cancer. 2017;5:36.View ArticlePubMedPubMed CentralGoogle Scholar
- Locke FL, Neelapu SS, Bartlett NL, et al. Abstract CT019: Primary results from ZUMA-1: a pivotal trial of axicabtagene ciloleucel (axicel; KTE C-19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Cancer Research. Washington, DC. 2017;77(13 Supplement): CT019-CT.Google Scholar
- Weintraub A. Kite Pharma's CEO On Bringing Cancer-Killing T-Cells To The FDA. http://www.forbes.com/sites/arleneweintraub/2016/10/20/kite-pharmas-ceo-on-bringing-cancer-killing-t-cells-to-the-fda/#29101afa29fe. Accessed 5 July 2017.